Concord Drugs (BOM:538965) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:538965 Concord Drugs Ltd BOM:538965
67 GF Score
Price ₹71.23
GF Value ₹60.93
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Concord Drugs Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Concord Drugs Valuation Rank Related Terms

BOM:538965
67GF Score
Concord Drugs Ltd BOM:538965
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹71.23 is trading 16.9% above its estimated GF Value™ of ₹60.93. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • Valuation Rank:
  • GF Value™: ₹60.93 vs. price of ₹71.23 (16.9% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
67GF Score

Get the complete analysis for BOM:538965

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹71.23
Price
₹60.93
GF Value